Free Trial
NASDAQ:TECH

Bio-Techne (TECH) Stock Price, News & Analysis

Bio-Techne logo
$62.90 -1.47 (-2.28%)
Closing price 03/10/2025 04:00 PM Eastern
Extended Trading
$62.95 +0.05 (+0.08%)
As of 03/10/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bio-Techne Stock (NASDAQ:TECH)

Key Stats

Today's Range
$62.40
$64.80
50-Day Range
$60.12
$78.75
52-Week Range
$58.98
$85.57
Volume
2.47 million shs
Average Volume
1.04 million shs
Market Capitalization
$9.94 billion
P/E Ratio
63.54
Dividend Yield
0.51%
Price Target
$82.14
Consensus Rating
Moderate Buy

Company Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Remove Ads

Bio-Techne Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

TECH MarketRank™: 

Bio-Techne scored higher than 96% of companies evaluated by MarketBeat, and ranked 31st out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bio-Techne has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bio-Techne's stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Techne are expected to grow by 17.96% in the coming year, from $1.67 to $1.97 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Techne is 63.54, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.49.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Techne is 63.54, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.92.

  • Price to Earnings Growth Ratio

    Bio-Techne has a PEG Ratio of 2.88. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bio-Techne has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bio-Techne's valuation and earnings.
  • Percentage of Shares Shorted

    3.34% of the float of Bio-Techne has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Techne has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Bio-Techne has recently increased by 28.61%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bio-Techne has a dividend yield of 0.50%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Bio-Techne does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Bio-Techne is 32.32%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.24% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

  • Read more about Bio-Techne's dividend.
  • Percentage of Shares Shorted

    3.34% of the float of Bio-Techne has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Techne has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Bio-Techne has recently increased by 28.61%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bio-Techne has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Bio-Techne this week, compared to 8 articles on an average week.
  • Search Interest

    Only 7 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Techne insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,157,753.00 in company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Bio-Techne is held by insiders.

  • Percentage Held by Institutions

    98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Techne's insider trading history.
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock News Headlines

“Amazon Coin” set to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
Bio-Techne price target lowered to $70 from $80 at Citi
See More Headlines

TECH Stock Analysis - Frequently Asked Questions

Bio-Techne's stock was trading at $72.03 at the beginning of the year. Since then, TECH stock has decreased by 12.7% and is now trading at $62.90.
View the best growth stocks for 2025 here
.

Bio-Techne Co. (NASDAQ:TECH) released its quarterly earnings results on Wednesday, February, 5th. The biotechnology company reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.38 by $0.03. Bio-Techne had a trailing twelve-month return on equity of 12.73% and a net margin of 13.22%.

Bio-Techne shares split before market open on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were issued to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

The following companies are subsidiaries of Bio-Techne: MoGen Biotechnologies, Exosome Diagnostics, Quad Technologies, Advanced Cell Diagnostics, Space Import-Export Srl, Zephyrus Biosciences, Cliniqa, and more.

Top institutional investors of Bio-Techne include Vanguard Group Inc. (11.70%), Price T Rowe Associates Inc. MD (6.71%), Ameriprise Financial Inc. (2.96%) and Bamco Inc. NY (2.60%). Insiders that own company stock include Charles R Kummeth, Roeland Nusse, Kim Kelderman, Brenda S Furlow, Robert V Baumgartner, John L Higgins and Amy E Herr.
View institutional ownership trends
.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Techne investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

Last Earnings
2/05/2025
Ex-Dividend for 2/28 Dividend
2/14/2025
Dividend Payable
2/28/2025
Today
3/10/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:TECH
Employees
3,100
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$82.14
High Stock Price Target
$95.00
Low Stock Price Target
$68.00
Potential Upside/Downside
+30.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
63.54
Forward P/E Ratio
37.66
P/E Growth
2.88
Net Income
$168.10 million
Pretax Margin
15.53%

Debt

Sales & Book Value

Annual Sales
$1.20 billion
Cash Flow
$2.22 per share
Price / Cash Flow
28.30
Book Value
$13.15 per share
Price / Book
4.78

Miscellaneous

Free Float
151,923,000
Market Cap
$9.94 billion
Optionable
Optionable
Beta
1.30

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:TECH) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners